BidaskClub upgraded shares of BioTelemetry (NASDAQ:BEAT) from a hold rating to a buy rating in a research note released on Wednesday morning.
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of BioTelemetry from a hold rating to a sell rating in a report on Thursday, February 8th. Dougherty & Co reissued a buy rating and issued a $40.00 price target on shares of BioTelemetry in a report on Wednesday, November 8th. SunTrust Banks assumed coverage on shares of BioTelemetry in a report on Monday, October 23rd. They issued a buy rating and a $41.00 price target on the stock. Finally, Raymond James Financial assumed coverage on shares of BioTelemetry in a report on Thursday, October 26th. They issued an outperform rating and a $37.00 price target on the stock. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. BioTelemetry currently has an average rating of Buy and a consensus price target of $42.86.
Shares of BioTelemetry (NASDAQ:BEAT) opened at $34.25 on Wednesday. The stock has a market cap of $1,090.00, a price-to-earnings ratio of 26.15, a price-to-earnings-growth ratio of 1.50 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.60 and a debt-to-equity ratio of 0.75. BioTelemetry has a fifty-two week low of $23.30 and a fifty-two week high of $39.20.
TRADEMARK VIOLATION NOTICE: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://stocknewstimes.com/2018/02/18/biotelemetry-beat-raised-to-buy-at-bidaskclub-2.html.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.